In addition, Wang et al. [229] discovered a novel orally active necroptosis antagonist bardoxolone (CDDO 7) that seems to target Hsp90, leading to diminished RIPK1 and RIPK3 phosphorylation and providing efficient protection against TNF-α-induced necroptosis in mice models of both SIRS and cerebral I/R injury. Here, RIPK1 is linked to systemic inflammatory response syndrome.